Thin metal sources carrying radium-224 are placed inside a solid tumour. As the radium decays, short-lived radioactive atoms leave the source, spread a few millimetres through the tumour and give off alpha particles, a radiation that does heavy damage over a very short distance. The human evidence so far is small studies with no comparison group.
Alpha particles deposit their energy over less than a tenth of a millimetre, too short a range for a sealed source to treat a tumour. Diffusing alpha-emitter radiation therapy, proposed at Tel Aviv University by Arazi, Kelson, Keisari and colleagues in 2007, gets round this by fixing radium-224 to an implanted source and letting its decay products do the travelling: radon-220, polonium-216 and lead-212 atoms recoil off the surface, disperse in the tissue and deliver dose through their own alpha decays. In mouse squamous cell carcinomas the method produced a necrotic region 5 to 7 mm across around each source, and lead-212 was found to leave the tumour through the blood.
The first-in-human study (Popovtzer and colleagues, 2020) treated 31 skin and head and neck squamous cell carcinomas in 28 patients, 42% of the lesions previously irradiated. Of 28 lesions assessed, 22 (78.6%) had a complete response and 6 a partial response; 5 of the 22 complete responders relapsed locally at a median of 4.9 months, with a median follow-up of 6.7 months. Acute toxicity was mostly local pain, redness, swelling and mild skin ulceration. In the brain, the REGAIN study in recurrent glioblastoma had treated eight patients by November 2026 (interim, sponsor-reported; see the trial record).
Alpha Tau Medical, the developer, states that Alpha DaRT has marketing approval in Japan for unresectable locally advanced or locally recurrent head and neck cancer and in Israel for squamous cell carcinoma of the skin and oral cavity, and that it is otherwise investigational. No randomised comparison with standard radiotherapy or brachytherapy has been published in the sources read here.
Sources impregnated with radium-224 release radon-220, polonium-216 and lead-212 atoms by recoil; the atoms disperse inside the tumour and deliver a high dose through their alpha decays (Arazi 2007).
Query for this technology: (TITLE:"Diffusing alpha-emitter radiation therapy" OR ABSTRACT:"Diffusing alpha-emitter radiation therapy" OR TITLE:"Alpha DaRT" OR ABSTRACT:"Alpha DaRT" OR TITLE:"Diffusing alpha-emitters radiation therapy" OR ABSTRACT:"Diffusing alpha-emitters radiation therapy" OR TITLE:"Intratumoural diffusing alpha emitters" OR ABSTRACT:"Intratumoural diffusing alpha emitters") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Diffusing alpha-emitter radiation therapy (Alpha DaRT), not a curated reading list.
Shares Brachytherapy, Head and neck squamous cell carcinoma.
Shares Tel Aviv University, Glioma & glioblastoma.
Shares Brachytherapy, Head and neck squamous cell carcinoma.
Shares Brachytherapy, Glioma & glioblastoma.
Shares Brachytherapy, Head and neck squamous cell carcinoma.
Shares Brachytherapy, Head and neck squamous cell carcinoma.
Shares Targeted alpha therapy, Glioma & glioblastoma, Head and neck squamous cell carcinoma.
Shares Brachytherapy, Head and neck squamous cell carcinoma.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/